TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30142422
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fish oil (FO) and cytarabine (AraC)
Study: 30143455
Drug: Loss to
Normalized name: SALICYLIC ACID 0.3 in 100 mL / NIACINAMIDE 0.3 in 100 mL / MENTHOL 0.3 in 100 mL TOPICAL LIQUID [PHS Hair Science Fem Hair Loss Tonic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loss to follow-up after starting treatment
Study: 30143455
Drug: Treatment initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiation likelihood based on site type
Study: 30146701
Drug: ZX008 (fenfluramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 (fenfluramine HCl) at an initial dose of 0.2 mg/kg/d, with escalations up to 0.8 mg/kg/d or 30 mg/d every 4 weeks in nonresponders.
Study: 30146701
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to ZX008 treatment.
Study: 30149145
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (canagliflozin)
Study: 30149145
Drug: Incretin agents
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incretin agents (liraglutide)
Study: 30149145
Drug: Incretin agents
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incretin agents (sitagliptin)
Study: 30151972
Drug: Marzeptacog alfa
Normalized name: Marzeptacog alfa (activated)
DrugBank: Marzeptacog alfa (activated) (DB15278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marzeptacog alfa (activated) at intravenous doses up to 30 μg kg
Study: 30152164
Drug: Hybrid cognitive-behavioral
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid cognitive-behavioral therapy intervention
Study: 30153232
Drug: Ceftolozane/tazobactam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam (single intravenous dose, age-based)
Study: 30153232
Drug: Ceftolozane/tazobactam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam (single intravenous dose)
Study: 30153529
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone deficiency (GHD) patients after aerobic exercise
Study: 30153790
Drug: High-dose behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose behavioral treatment (DTI plus relaxation training)
Study: 30153790
Drug: Low-dose behavioral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose behavioral treatment (DTI plus relaxation training)
Study: 30154193
Drug: Intratumoral SD-101
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral SD-101 in combination with pembrolizumab
Study: 30154228
Drug: Hsp90 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hsp90 inhibitor luminespib (formerly AUY922)
Study: 30154228
Drug: EGFR inhibitors
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR inhibitors (first-, second-, and third-generation)
Study: 30154229
Drug: Annual MG
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual MG screening plus biannual MRI screening
Study: 30155282
Drug: HTC-gel (Thealoz
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTC-gel (Thealoz Duo Gel) - hyaluronic acid, trehalose, and carbomer
Study: 30156984
Drug: Capmatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capmatinib (400 mg twice per day) plus Gefitinib (250 mg once per day)
Study: 30156984
Drug: Capmatinib (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capmatinib (100-800 mg once per day or 200-600 mg twice per day) plus Gefitinib (250 mg once per day)
Study: 30157702
Drug: HPTN 052
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPTN 052 clinical trial care and treatment
Study: 30157803
Drug: Accelerated BEP
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated BEP chemotherapy
Study: 30157803
Drug: Standard BEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BEP chemotherapy
Study: 30158288
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg per day for 56 days
Study: 30158840
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with HBOT for 10 sessions (combination therapy)
Study: 30161147
Drug: Option B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Option B PMTCT regimen (three-drug ART throughout pregnancy and breastfeeding, regardless of maternal CD4 count)
Study: 30165500
Drug: Fruit consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit consumption in RTRs with eGFR > 45 mL/min/1.73 m2
Study: 30165651
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of live herpes zoster vaccine (ZVL)
Study: 30166073
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg twice daily) plus aspirin (75-100 mg daily) for 1 month, followed by ticagrelor monotherapy for 23 months
Study: 30166073
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy (75-100 mg aspirin daily plus either 75 mg clopidogrel daily or 90 mg ticagrelor twice daily for 12 months), followed by aspirin monotherapy for 12 months
Study: 30166291
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) syndrome-targeted therapies
Study: 30166291
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) four diagnostic methods
Study: 30167089
Drug: Alpelisib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (300 mg, n=6) plus paclitaxel (80 mg/m2)
Study: 30167089
Drug: Alpelisib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (250 mg, n=4) plus paclitaxel (80 mg/m2)
Study: 30167089
Drug: Alpelisib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (150 mg, n=9) plus paclitaxel (80 mg/m2)
Study: 30167310
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg two times a day
Study: 30168134
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks)
Study: 30168356
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) in addition to physiotherapy
Study: 30169182
Drug: AAV2-hAADC gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-hAADC gene therapy (bilateral intraputaminal injections, dosage not specified)
Study: 30169223
Drug: Elvitegravir 150
Normalized name: elvitegravir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily
Study: 30169669
Drug: Low antenatal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low antenatal vitamin D status (<30 nmol/L and <50 nmol/L)
Study: 30169669
Drug: Maternal 25(OH)D
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal 25(OH)D (per 10 nmol/L)
Study: 30169669
Drug: Cord 25(OH)D
Normalized name: cow umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord 25(OH)D (per 10 nmol/L)
Study: 30170630
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) and low-dose ipilimumab (1 mg/kg)
Study: 30170630
Drug: Empiric immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric immune suppressive therapy (high dose steroids, tacrolimus, therapeutic plasma exchange)
Study: 30171797
Drug: Measles-mumps-rubella vaccine
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-mumps-rubella vaccine (MMR)
Study: 30172345
Drug: R2-CHOP (Rituximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone + 25 mg oral Lenalidomide per day on days 1-14 for 6 cycles every 3 weeks)
Study: 30172739
Drug: Estimated antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated antipsychotic dopamine receptor occupancy
Study: 30173210
Drug: Intracavernous autologous
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) injections
Study: 30174951
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg and pregabalin 75mg twice daily starting from 3 days before the operation
Study: 30175123
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant (Ozurdex, Allergan)
Study: 30176833
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and hormonal therapy
Study: 30176875
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow concentrate (BMC) and platelet products injection
Study: 30176878
Drug: Iconic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iconic Therapy
Study: 30176878
Drug: Structured Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Support Therapy
Study: 30176976
Drug: Positive Airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Airway Pressure (PAP) therapy adherence (h/night)
Study: 30177021
Drug: Fostamatinib (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib (an oral prodrug SYK inhibitor)
Study: 30178032
Drug: Nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) administered on days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxic effects.
Study: 30178312
Drug: Homozygous G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homozygous G mutant
Study: 30178312
Drug: Gln27Glu G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gln27Glu G mutant group
Study: 30178481
Drug: CTL019 infusion
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTL019 infusion
Study: 30179569
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (Bv) 1.8 mg/kg once every 3 weeks followed by six cycles of AVD chemotherapy and four consolidative doses of Bv
Study: 30179569
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (Bv) and AVD chemotherapy
Study: 30180050
Drug: Uterosacral ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral ligament suspension (USLS) with a size 'small' titanium vascular clip applied to the base of each suture.
Study: 30181045
Drug: Double-dose (DD)
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-dose (DD) influenza vaccine (30 µg antigen)
Study: 30181045
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) influenza vaccine (15 µg antigen)
Study: 30181172
Drug: Additional agents
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional agents tailored by disease severity
Study: 30181185
Drug: Violet LED
Normalized name: acid violet 43
Approvals — FDA: no, EMA: no, PMDA: no
Description: Violet LED treatment (405 nm)
Study: 30185228
Drug: pictilisib (GDC-0941)
Normalized name: calcium carbonate
DrugBank: Pictilisib (DB11663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pictilisib (GDC-0941) plus paclitaxel (90 mg/m²)
Study: 30185431
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) 25 mg/m2
Study: 30186623
Drug: Fimasartan (Kanarb),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (Kanarb), switched to after 8 weeks of treatment
Study: 30187270
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (HFNT)
Study: 30187599
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a 180 μg/wk added to ongoing nucleos(t)ide analogue therapy
Study: 30188978
Drug: Allometric miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allometric miltefosine dosing for 28 days
Study: 30188978
Drug: Linear miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linear miltefosine dosing (2.5 mg/kg/day for 28 days)
Study: 30190299
Drug: Regorafenib-related treatment-emergent
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib-related treatment-emergent adverse events (TEAEs)
Study: 30190302
Drug: TRC105 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib (initially at 5 mg b.i.d. and escalated to a maximum of 10 mg b.i.d.)
Study: 30190302
Drug: TRC105 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib
Study: 30191053
Drug: Hepatic intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic intra-arterial chemotherapy (IACHT) with Epirubicin-Cisplatin and systemic chemotherapy (SCHT) with Capecitabine or 5-fluorouracil, followed by gemcitabine-based maintenance therapy.
Study: 30191502
Drug: Behavioral/pharmacological treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral/pharmacological treatment
Study: 30191523
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg orally three times daily plus hydrocortisone (20 mg in the morning and 10 mg at night) and lenalidomide 25 mg orally daily for 21 days in a 28-day cycle and aspirin 75 mg daily
Study: 30191864
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with a dose of 40 Gy in 5 fractions of 8 Gy
Study: 30192444
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (maximum dose of 21.0 mg/d, applied daily with dose escalation)
Study: 30194585
Drug: Single 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 40 mg oral dose of imarikiren
Study: 31203649
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Treatment for Insomnia (BBTi)
Study: 30196853
Drug: AAV8-RS1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e9 vg/eye
Study: 30196853
Drug: AAV8-RS1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e10 vg/eye
Study: 30196853
Drug: AAV8-RS1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e11 vg/eye
Study: 30198934
Drug: Alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 10 µg·kg(-1)
Study: 30199593
Drug: All-oral DAA
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-oral DAA combinations
Study: 30200905
Drug: HIV self-testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV self-testing (HIVST) conducted by MSM, either finger prick or oral fluid, without assistance from a trained counselor
Study: 30200905
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid HIV self-testing
Study: 30201761
Drug: Avadomide (CC-122)
Normalized name: Avadomide
DrugBank: Avadomide (DB14857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avadomide (CC-122) at doses ranging from 0.5-3.5 mg, 28-day continuous dosing cycles
Study: 30201761
Drug: Avadomide (CC-122)
Normalized name: Avadomide
DrugBank: Avadomide (DB14857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avadomide (CC-122)
Study: 30201849
Drug: Combined immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunosuppressive therapy (rituximab, high-dose pulsed steroids, cyclophosphamide until remission, followed by maintenance therapy with azathioprine)
Study: 30201849
Drug: Combined immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunosuppressive therapy
Study: 30203081
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of Takeda's bivalent norovirus virus-like particle (VLP) vaccine candidate
Study: 30204542
Drug: Maternal milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal milk lutein concentrations (sample 1: 6.5 μg/dL, sample 2: 7.7 μg/dL)
Study: 30204542
Drug: Maternal milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal milk zeaxanthin concentrations (sample 1: 1.6 μg/dL, sample 2: 1.7 μg/dL)
Study: 30204885
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS-PL) with 20 mg Fe
Study: 30204885
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA) with 60 mg Fe + 400 µg folic acid
Study: 30205124
Drug: Metastasis-directed stereotactic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastasis-directed stereotactic body radiation therapy (mdSBRT)
Study: 30205231
Drug: Ruxolitinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib therapy followed by reduced-intensity conditioning (RIC) regimen
Study: 30205886
Drug: IV sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sodium nitrite 25 mg (low dose)
Study: 30205886
Drug: IV sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sodium nitrite 60 mg (high dose)
Study: 30205886
Drug: IV sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sodium nitrite (both doses)
Study: 30207748
Drug: Technosphere insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere insulin (TI), n=26
Study: 30207748
Drug: Technosphere insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere insulin (TI) compliant group (n=15)
Study: 30207748
Drug: Insulin aspart,
Normalized name: insulin aspart, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin aspart, n=34
Study: 30208209
Drug: Continued appropriate
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued appropriate medical therapy (CAMT)
Study: 30209556
Drug: Gemcitabine, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, cisplatin, and dexamethasone (GDP) combined with methotrexate (MTX) and pegaspargase (PEG-L)
Study: 30212436
Drug: Inguinal lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inguinal lymph node biopsy at baseline and/or after antiretroviral therapy (median 48 weeks after therapy)
Study: 30213581
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of baseline concentrations of COL3A1 and anti-CSF2
Study: 31576181
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants (TTI)
Study: 30214408
Drug: Adjunctive everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive everolimus (Low exposure: 3-7 ng/mL)
Study: 30214408
Drug: Adjunctive everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive everolimus (High exposure: 9-15 ng/mL)
Study: 30216219
Drug: CTC-positive (≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC-positive (≥1 CTC/7.5 mL) in high-risk patients
Study: 30217223
Drug: Transcatheter delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter delivery of autologous bone marrow-derived advanced therapy medicinal product CD133
Study: 30217228
Drug: Salvianolate injection
Normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvianolate injection